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Abstract
High-risk prostate cancer patients can receive treatment of both the pelvic lymph nodes and
seminal vesicles, in addition to the prostate based on an estimated risk of lymph node spread. Due
to the large volume being irradiated, these patients could be an attractive sub-group for proton
therapy. The primary advantages of proton therapy is that it causes less damage to healthy sur-
rounding tissues than photon therapy dose and improves the conformity of the dose to the target.
In regard to normal tissue, proton therapy therefore provides great potential in sparing normal
tissue and reduce unwanted side-effects, but if the reduced dose leads to a reduction in toxicity has
yet to be documented. The involvement of three target structures and the independent motion of
these regions make delivery of the treatment with protons challenging.
Adapting the treatment to the target motion of the patients during the course of treatment
could be a solution [Yan D. et al., 2010]. A resource effective method since online re-optimisation
is not yet feasible when delivering the treatment, can be to construct a plan library with different
positions of the prostate in regards to the lymph nodes, which previously has been applied for
radiotherapy [Xia P. et al., 2010]. This Master project will investigate if this strategy can be
extended to proton therapy. The plan library was generated based on an initial analysis of prostate
motion relative to bony anatomy in 18 patients (Study A).
The output from study A was then used as an input for study B. In study B, we created a
pool of three plans in addition to a standard plan for each patient basing on a planning computed
tomography (pCT) and optimized each plan to accommodate a presumed prostate position. The
three plans were for the prostate in three different locations with respect to the pelvic lymph
nodes, including the original prostate contour and two contours shifted +/-5mm in an anterior-
posterior (AP) direction and +/-4.6mm in cranial-caudal (CC) direction simultaneously. Prostate
only (CTV67.5), prostate together with seminal vesicles (CTV60) and lymph nodes (CTV50) were
the clinical target volumes (CTVs); and planning target volumes (PTVs) were created around the
CTVs with an isotropic margin of 5mm. We compared this strategy to the standard treatment
strategy with respect to the doses on the targets, rectum and bladder. The standard plan had a
larger margin compared to the plan library with 5mm margin for PTV50 around CTV50, 3mm
margin in the left-right and 10mm margins in both the cranial-caudal and anterior-posterior direc-
tions for PTV67.5 around CTV67.5; and 5mm margin in left-right and 10mm in both cranial-caudal
and anterior-posterior directions for PTV60 around CTV60. The prostate margin was determined
uisng the Van Herk’s formula as part of the motion analysis in study A. The results showed similar
doses to the targets as in the standard treatment approach but with reduced gEUD to the rectum
(k=12) and bladder (k=8). Similar doses were also obtained for both small (k=4) and large (k=4)
bowels in the two strategies. The plan library approach for treatment of high-risk prostate cancer
patients therefore proved feasible.
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Chapter 1: Introduction
1.1 High Risk Prostate Cancer and its treatment
There is no exact definition of high risk prostate cancer. Cancer incidences and survival generally
for prostate and especially high-risk, clinically localised prostate cancer was defined as any com-
bination of the following factors: a prostate-specific antigen (PSA) score >20 ng/ml, a Gleason
score of 8 - 10, or clinical stage T2c or greater [D’Amico et al., 2002]. More recently, the National
Comprehensive Cancer Network and European Association of Urology (EAU) modified this defi-
nition to include any combination of a clinical T3, a PSA score >20 ng/ml, or a Gleason score of
8 - 10 [Albert J. et al., 2014]. Independent of the definition used, the optimal treatment for these
men remains unknown, but the common treatments for prostate cancer in general include surgery,
radiation therapy (RT), or primary androgen-deprivation therapy. External beam radiation ther-
apy (EBRT) is the most widely used type of radiation therapy, and it most often uses photon
beams. The radiation comes from a machine outside the body and is focused on the cancer, by
irradiating the patients from various angles. This type of radiation is most often given by machines
called linear accelerators (LINACS). External beam radiation can be used to treat large areas of
the body. It can also be used to treat more than one area, such as the main tumor and the nearby
lymph nodes.
Trials and experience from larger treatment centres show that when RT is adequately admin-
istered, it can achieve cure rates that is comparable to surgical treatment for localised prostate
cancer [Chuba et al., 2001; Kupelian et al., 2002; Potosky et al., 2000]. Furthermore, studies on
quality of life and side effects indicate that, despite a wide range of complications, the overall im-
pact of these treatment modalities on the well being of the patients is comparable [Kupelian et al.,
2002; Madalinska et al., 2001; Wei et al., 2002]. The use of whole pelvic radiotherapy (WPRT) is
controversial in patients with locally advanced prostate adenocarcinoma [Ayal A. A. et al., 2009].
Theoretically, WPRT, in comaprison to prostate-only RT (PORT), improves outcome in patients
with advanced or aggressive PCa by sterilizing the locoregional lymph nodes on assumption that
the lymph nodes may harbour occult disease before more distant sites [Ayal A. A. et al., 2009, Lisa
K. Morikawa et al. 2011]. WPRT is prescribed since it is difficult to detect lymph node metastases
clinically as prostate cancer has the potential to spread to numerous lymph node groups. Besides,
there is inaccuracy in determination of lymph node involvement of patients with prostate can-
cer due to many reasons such as poor sensitivity of CT, magnetic resonance imaging (MRI), and
positron emission tomography (PET). If patients in the PORT and WPRT cohorts were to have
equivalent intrinsic tumor characteristics, it is possible that the WPRT arm would have displayed
improved biochemical-disease free survival compared with the PORT arm. With regard to the
adverse effects, acute toxicity appeared to be greater in the WPRT patients, but no difference
was found in the incidence of late toxicity [Ayal A. A. et al., 2009]. However, patients undergoing
WPRT displayed an increased incidence of acute gastrointestinal toxicity relative to those treated
with PORT and a greater percentage of WPRT patients experienced acute genitourinary toxicity,
although this difference was not statistically significant. No difference in late genitourinary or
gastrointestinal toxicity was seen between the two cohorts [Ayal A. A. et al., 2009].
At Haukeland University Hospital, high-risk prostate cancer patients get treatment of the
prostate, lymph nodes and seminal vesicles. A high dose of 67.5 Gy is delivered to the prostate
only, a dose of 60 Gy to both the prostate and seminal vesicles while a low dose of 50 Gy is delivered
to the lymph nodes only. The three dose levels are delivered as a simultaneous integrated boost
(SIB) delivered in 25 fractions over a time interval of five weeks.
1.2 History of Radiotherapy
Radiotherapy refers to the treatment of disease (cancer) with radiation, especially by selective
irradiation with x-rays or other ionizing radiation such as gamma rays and charged particles.
RT delivery can be done as EBRT, which may be conventionally fractionated RT(CFRT) with
intensity modulated radiation therapy (IMRT) or protons, hypofractionated RT (HFRT) with
IMRT or protons, or delivered as stereotactic body RT (SBRT); or as brachytherapy (BT), which
can be either high dose rate BT (HDR-BT) or low dose rate BT (LDR-BT). RT dates back to the
discovery of x-rays.
Wilhelm Rontgen announced the discovery of X-rays on November 30th, 1895. At the end of
January 1896, approximately 60 days after Rontgen’s announcement, Emil Grubbe, a second-year
medical student treated the first two patients with X-rays. The first was breast cancer and the
other, skin lesions due to Tuberculosis and hence the birth of radiation therapy [Lederman M.,
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1981]. Since then, radiation therapy has been constantly developing for the last 120 years, but the
aim has always been the same, to deliver as close as possible to 100% of the prescribed dose to
the target volume, while at the same time spare as much of the healthy tissue as possible. The
advancements in that line since 1895 have been tremendous.
In the beginning, treatments were available for only superficial tumors and melanomas, due
to the relatively low photon energies that were achievable. Years later, both supervoltage X-ray
tubes and LINACS were developed, which allowed for treatment of more deep-seated tumors. As
early as 1906, different patterns of radiosensitivity were demonstrated, and in 1934 radiation dose
deliverance using fractionation, as opposed to delivering the entire dose at the same time, was
proposed [Thariat J. et al., 2012]. This technique together with many more have led to better
cure rates for cancer and less damage to healthy tissue [Thariat J. et al., 2012]. In 1953, the
first LINAC for photon therapy was installed in London. This was only a few years after Robert
Wilson’s emphasis on the therapeutic advantage of using protons in radiation therapy in his article
Radiological Use of Fast Protons [R. R. Wilson, 1946]. He also proposed the use of heavier ions. As
stated, the first patient was treated with protons as early as 1954, while treatments using helium
and neon ions were first done in 1957 and 1975, respectively [Amaldi U. and Kraft G., 2005]. After
the 1960s, the definitions of target volumes and organs at risk were made by the International
Commission on Radiation Units and Measurements (ICRU) and also treatment planning systems
arrived, allowing more accurate treatment planning [Thariat J. et al., 2012].
Another break through by Godfrey Hounsfield by developing the CT scanner in 1971 paved way
to radiation planning shifting from two to three dimensions later when more than one slice was
acquired with CT. Consequently, CT-based simulations and dose planning were introduced, and
computer driven multileaf collimators (MLC) conforming the radiation field, were developed in the
1990s. In the early 2000s, intensity-modulated radiation therapy (IMRT), followed by volumetric
modulated arc therapy (VMAT) and image guided radiation therapy (IGRT) had a significant
effect on the success of radiation therapy. The many delivery techniques and methods developed
in the last century have made it possible to personalize the radiation therapy techniques based
on different types of patients, tumor extents and locations. However, the spatial dose distribution
from photons must unfortunately follow the laws of physics, meaning that the conformity of high
dose volumes with photons is actually as good as with protons, but at the proce of a larger ”dose
bath”.
1.3 Proton Therapy
Proton therapy has been used since 1954. Cyclotron facilities that produced proton beams previ-
ously existed for physics research, but in 1946, Robert Wilson first proposed they be used for the
treatment of cancer.This relates to the importance of highly localized deposition of energy as a
way of increasing the dose to the tumour, while minimizing the dose to normal tissues [Pugh T.J.
and Lee A.K., 2014]. Two years later, researchers at the Lawrence Berkeley Laboratory conducted
extensive studies on protons and confirmed the predictions made by Wilson. The first treatments
on humans consisted of radiation to destroy the pituitary gland in patients with hormone-sensitive
metastatic breast cancer [Shinohara E., 2016]. This treatment successfully stopped the pituitary
from making the hormones that stimulated the cancer cells to grow. In the 1950’s, the treatments
were effectively duplicated on patients at a facility in Uppsala, Sweden [Shinohara E., 2016].
This led to the Harvard Cyclotron Facility using protons for medical treatments. They began
treatment of the pituitary gland and developed specialized techniques for treating other condi-
tions such as arteriovenous malformations (AVM) [Shinohara E., 2016]. During the 1960’s, these
facilities worked to expand proton treatments to include choroidal melanomas, chondrosarcomas,
chordomas, and various cancers located in the brain. However, this early work was limited due to
the inability to perform 3-D imaging and the reliance on treatment in facilities primarily dedicated
to physics research [Shinohara E., 2016].
In the 1980’s, design and construction began on the first dedicated clinical proton facility at Loma
Linda University Medical Center in California, which has treated over 18,000 patients with proton
therapy.
Over 130,000 patients have now been treated with proton therapy worldwide [Shinohara E.,
2016]. There are 19 facilities operating in the U.S. with several facilities currently under construc-
tion or in the planning stages. Many experts argue that without clinical trials, the therapy is not
proven to be superior to x-ray therapy [Shinohara E., 2016]. Some centers are making clinical trials
a priority to help determine which cancers are best treated by protons.
Just as X-rays (also known as photons) are used to treat both benign and malignant tumors,
proton beams can be used to irradiate tumors in a similar way, which is referred to as proton
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therapy. There is no significant difference in the biological effects of protons versus photons (x-
rays). Protons deliver a dose of radiation much more precisely than photons. After they enter
the body, protons release most of their energy within a defined depth and, unlike photons, deliver
only a minimal dose beyond this range. Therefore, the dose of radiation may, because of less
integrated dose (i.e. at entrance and exit), conform much tighter to the tumor and there may
be less damage to healthy tissue. As a result, the treating physician (a radiation oncologist) can
potentially prescribe an even greater dose to the tumor without increasing risk of unwanted side
effects. Proton beam therapy uses special machines, a cyclotron and synchrotron being the most
common, to generate and accelerate protons to speeds up to 60 percent the speed of light and
energies of up to 250MeV. A cyclotron is a device made of a cylindrical or spherical chamber
and uses a high-frequency alternating voltage or rapidly varying electric field to generate and
accelerate protons to high speeds which are normally used in used in production of radioactive
isotopes. Where as a synchrotron is made of a torus shaped tube,and uses varying electric and
magnetic fields to generate and accelerate protons to high speeds and they are used in most of
the large-scale facilities such as in carbon ion therapy. These high-energy protons are steered by
magnets toward the treatment room, and then to the specific part of the body being treated. About
154,203 patients have been treated with particle therapy from 1954-2015 out of which 131,240 were
treated with protons [Martin J., 2015]. In first generation proton machines, additional pieces of
equipment such as a degrader, a modulator wheel, a range shifter wheel are needed to modify
the range of the protons and the shape of the beam [Shinohara E., 2016]. Newer facilities make
similar adjustments by fine tuning the energy of the beam and the magnetic fields which guide
their path (”pencil beam scanning” or ”scanning beam”). A beam degrader can be used to change
the energy of the proton beam. This energy selection system degrades the initial beam produced
by the cyclotron to produce several different lower energies [Shinohara E., 2016]. This allows the
beam energy to be modulated such that a variety of depths within the tissue can be treated. These
modifications guide the proton beam to precise locations in the body where they deliver the energy
needed to inactivate tumor cells.
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Chapter 2: Theoretical background of (radio and) particle
therapy
Photon therapy and proton therapy are both radiotherapy techniques but the former uses photons
to irradiate diseased tissues while the latter uses beams of energetic protons, which have very
different physical properties. Before reaching the tumor, both radiation types pass/penetrate
through the patients skin and surrounding tissues (entrance dose). To deliver a high dose to the
target, multiple fields are usually used as shown in the Figure 1 below.
Figure 1: Illustration of multiple fields in radiotherapy [Alex T., Massachusetts General Hospital,
1994].
In this chapter, physical interactions of photons and protons will be discussed as these forms the
basis of how treatment is performed. Biological effects and relative biological effectiveness (RBE)
will also be presented to understand how radiations interact with the tissues. Last but not least,
techniques of photon therapy and proton therapy will be presented for the understanding of how
these modalities are used.
2.1 Physical interaction of photons
The photon, with no mass and no charge, is highly penetrating and delivers a dose throughout any
volume of tissue irradiated. However, most of the radiation is delivered only 0.5 to 3 cm from the
patients skin, depending on the energy it was initially given. It then gradually attenuates until it
reaches the target ,and as photons are not all stopped by human tissue, they leave the patient’s
body and continue to emit radiation (exit dose).
High-energy photons is the most common form of radiation used in RT today [Michael J.G. et al.,
2005]. Photons are either released from the nucleus of a radioactive atom and are known as gamma
rays or they are created electronically, such as in a clinical LINAC, and they are known as x-rays.
Photon absorption in human tissue is determined by the energy of the radiation, as well as the
atomic structure of the tissue in question. Since the energies of the photons coming from LINAC
has a distribution of energies, the voltage of the LINAC is usually used, i.e. MV, to describe the
photon energy in clinical practice.
2.1.1 Photon-tissue interactions
Three interactions describe photon absorption in tissue: the photoelectric effect, Compton effect,
and pair production;
(a) Photoelectric effect
In this process, an incoming photon undergoes a collision with a tightly bound electron. The
photon transfers practically all of its energy to the electron and ceases to exist. The electron
departs with most of the energy from the photon and begins to ionize surrounding molecules. This
interaction depends on the energy of the incoming photon, as well as the atomic number of the
tissue; the lower the energy and the higher the atomic number,the more likely that a photoelectric
effect will take place [Michael J.G. et al., 2005].
An example of this interaction in practice can be seen on a diagnostic x-ray film. Since the atomic
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number of bone (13.8) is 60% higher than that of soft tissue (7.4), bone is seen with much more
contrast and detail than is soft tissue. The energy range in which the photoelectric effect predom-
inates in tissue is about 10-25 keV [Michael J.G. et al., 2005].
(b) Compton effect
Compton effect is the dominant photon-tissue interaction for the treatment of cancer with photons.
In this case, a photon collides with a ”free electron,” that is, one which is not tightly bound to the
atom. Unlike the photoelectric effect, in the Compton interaction both the photon and electron
are scattered. The Compton effect (also called Compton scattering) is when a high-energy photon
collides with a target,following release of a loosely bound electron from the outer shell of the atom
or molecule [Jared H., 2005].
The photon can then continue to undergo additional interactions, albeit with a lower energy.
The electron begins to ionize with the energy given to it by the photon. The probability of a Comp-
ton interaction is inversely proportional to the energy of the incoming photon and is independent of
the atomic number of the material. As a result, when an image of tissue is acquired using photons
in the energy range in which the Compton effect dominates (≈ 25 keV - 25 MeV), bone and soft
tissue interfaces are barely distinguishable. The Compton effect is the most common interaction oc-
curring clinically, as most radiation treatments are performed at energy levels of about 6 - 20 MeV.
(c) Pair production
In this process, a photon interacts with the nucleus of an atom, not an orbital electron. The photon
gives up its energy to the nucleus and, in the process, creates a pair of positively and negatively
charged electrons. In order for pair production to occur, the incoming energy of the interaction
must be above a threshold (1.02MeV) in order to create the pair- atleast the total rest mass energy
of the two particles and that the situation allows both energy and momentum to be conserved.
The positive electron (positron) ionizes until it combines with a free electron and annihilates into
two photons that scatter in opposite directions [Michael J.G. et al., 2005]. The probability of pair
production is proportional to the logarithm of the energy of the incoming photon and is dependent
on the atomic number of the material. The energy range in which pair production dominates is ≥
25 MeV. However, this interaction does occur to some extent in routine radiation treatment with
high-energy photon beams.
The graph below (Figure 2) shows the region where the different interactions dominate with respect
to the relative importance of the three main interaction mechanisms depending on the energy of
the incident photon and the nature of the absorbing material.
Figure 2: Graph of atomic mass, Z versus energy illustrating the dominance of the three different
interaction mechanisms of photons [Dr. James E. Parks, 2004].
2.2 Physical interaction of protons
The proton is a charged particle that gradually looses its velocity as it interacts with human
tissue. Proton has high energy when it enters the patient’s body and only a small radiation dose is
inadvertently deposited in normal tissues before the radiation reaches the tumour. The absorbed
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dose increases gradually with greater depth and lower speed, suddenly rising to a peak when the
proton is ultimately stopped. This peak is termed the Bragg peak (Figure 3).
Figure 3: Graph of relative dose against depth illustrating Bragg peak of protons [Timlin C. and
Jones B., 2010].
Proton being a charged particle just like any other charged particle with mass greater than the
electron rest mass, looses energy while traversing through matter basically due to collisions with
bound electrons. In these collisions an electron can either be raised to a higher shell in the ab-
sorbing atom (excitation) or it can be ejected from the atom (ionization). If the ejected electron
receives enough kinetic energy, it can cause further ionizations. These electrons are referred to as
δ - electrons [Kaderka R., 2011]. The energy loss per collision is typically very small, however, be-
cause of the high number of collisions per unit path length, a substantial fraction of the interacting
particle’s kinetic energy can be transferred to a relatively thin layer of matter [Leo W. R., 1994].
The mean energy loss per unit length for a charged particle traversing through matter is described







































Table 2.2.1 below shows the variables that are used in the Bethe-Bloch equation.
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Table 2.2.1: Relevant parameters used in Bethe-Bloch equation.
Symbol Definition Value or unit
ρ Density of material gcm−3
Z Atomic number of material
A Atomic mass of material gmol−1
z Charge number of incident particle
β νc of incident particle
me Electron mass MeV c
−1
m Mass of incident particle MeV c−1
c Speed of light in vacuum 2.998 x 108ms−1
γ Lorentz factor, 1√
1−β2
I Mean excitation potential eV
δ(βγ) Density effect correction
C Shell correction
NA Avogadro’s number 6.022 X 10
23mol−1
re Classical electron radious 2.818fm
ν Speed of incident particle ms−1
Wmax Maximum energy transfer in a single collision
The mean excitation potential, I, is in essence Planck’s constant, h, times the electrons average
orbital frequency, ν [Leo W. R., 1994]. Using a correctly determined excitation potential is of high
importance in particle therapy as the uncertainty of the excitation potential for tissues can be as
high as between 5 - 15% [Andreo P., 2009] and can alter the calculated energy loss, and thereby
the beam range by as much as 1.5% [Paganetti H., 2012].
The shell correction, C, is important at low energies, i.e. when the velocity of the incoming
particle approaches and becomes smaller than the orbital velocity of the electrons in the absorbing
material. The correction is applied in the energy range of 1 - 100 MeV, and the maximum correction
is about 6% [Sengbusch E. et al., 2009 ]. The δ-term, i.e. the density correction, is only relevant
for proton energies higher than for therapeutic purposes [Ziegler J. F., 1999, Sengbusch E. et al.,
2009]. The energy loss for a heavy charged particle is highly energy dependent and is therefore
mostly determined by the particle’s velocity. For non-relativistic particle energies, the first term
in equation (1) is predominant, and thus the energy loss has a 1β2 dependence. For even lower
energies, about 10MeV or less [Kaderka R., 2011], the Bethe-Bloch equation is no longer valid, and
phenomenological fitting formulas and other theories are used to describe the energy loss [Olive K.
A., 2014].
The amount of energy of the protons, controlling its depth, is energy dependent as it was given
by the cyclotron (via acceleration). The behaviour of the proton can be precisely determined and
the beam can be directed so that f energy, the proton has lost all its energy to the tissue and no
primary dose is given in the exit region.Proton therapy therefore allows to target tumours inside
the body, precisely localize the radiation dosage, and offering potential to greatly spare normal
tissue. The depth-dose curve comparing proton and photon is as shown in the Figure 4 below.
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Figure 4: Depth-dose curves for protons and photons [Stephanie L. and Riesterer O., 2013].
Not all protons of the same energy have the same range due to range straggling [Paganetti H.,
2012] as illustrated in Figure 5 below.
Figure 5: Energy-range relationship of monoenergetic proton beams [Paganetti H., 2012].
The range therefore needs to be defined for a beam of protons resulting in a broadened Bragg peak
or a spread-out Bragg peak (SOBP) as shown in Figure 6 below.
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Figure 6: Illustration of SOBP [Grayden M., 2014].
The plan parameters and patient positioning must be highly precise in order to obtain a high dose
within the tumor region while maximizing the protection of organs at risk (OAR). This makes the
uncertainty regarding the range of motion in human tissue one of the major hurdles of RT with
protons, meaning that particle therapy is more vulnerable to target motion than photon irradiation
[Yoon M. et al., 2008], also describing an increased sensitivity to target motion of PBT because of
deep dose depletion beyond the SOBP.
2.3 Biological effects
Ionizing radiations interacts with the living systems (cells) and affects their normal functioning.
The most radiosensitive part of a cell is the DNA molecule [Saha G. B., 2006]. If the DNA is
destroyed, it can lead to cell death [Borges H. L. et al., 2008].
Figure 7: Direct and indirect action of radiation on DNA [Rajamanickam B. et al, 2014].
Different kinds of radiation interact with DNA molecules in different ways as illustrated in
Figure 7 above. When a photon is absorbed in the cell, free electrons (δ-electrons) are produced.
For radiotherapeutic energies, this happens mainly through the Compton process [Hall E. J. and
Giaccia A. J., 2011]. These δ-electrons may further ionize atoms in the medium and are able to
split one or two of the DNA strands if they are close enough. This type of interaction is called
direct action and will in most cases lead to double-strand break (DSB). However, in photon therapy,
the majority of strand breaks, i.e. about 70%, are caused by the so-called indirect action [Kelley
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M. R., 2011]. In indirect action, the produced δ-electrons do not hit the DNA itself, but rather
interact with water in the cells. These interactions produce a free radical, OH, which further has
the ability to damage the DNA (Figure 7). The disadvantage of indirect action is that more often
than not, the damage to the DNA occurs by single-strand breaks (SSB), which is easier for the cell
to repair than DSBs [Saha G. B., 2006].
2.3.1 Dosimetry
Suitable units are used to determine the amount of damage to tissues due to ionizing radiation for
both radiation protection purposes and radiation therapy [Cember H. and Johnson T., 2008]. This
is important for the determination of the accuracy of the absorbed dose, since a small offset of
the tumor dose may result into underdosage, thereby failing to control the tumor, and overdosage,
may potentially result into damage to healthy (normal) tissue [Paganetti H., 2011].
It is therefore important to understand absorbed dose, equivalent dose and effective dose.
(a) Absorbed dose
Radiation damage on a tissue depends on the amount of energy deposited by radiation to the
tissue. It is proportional to the mean concentration of absorbed energy in the irradiated tissue.
ICRU defines absorbed dose as the mean energy imparted by ionizing radiation, ∆E, to a certain





The unit for absorbed dose is called Gray (Gy) in the SI system, where 1Gy = 1 Jkg . An important
thing to remember is that the energy lost by e.g. a proton beam is larger than the absorbed dose.
This is because a part of the beam’s energy will be transformed into neutral secondary particles,
e.g. photons and neutrons, which may deposit their energy outside the volume in question [Pa-
ganetti H., 2011].
(b) Equivalent dose
The different types of radiations have different biological effects on tissues. This difference was
introduced in 1977 as the equivalent dose [ICRP, 1977]. A weighting factor, wR, was suggested to
differentiate between different particles and energies.





where wR is the weighting factor for the different radiations, as shown in Table 2.3.1, and DT,R
is the absorbed dose averaged over the irradiated tissue(s). The unit for equivalent dose is Sievert
(Sv) defined as 1Sv = 1 Jkg [Mayles P. et al., 2007].
Table 2.3.1: Radiation weighting factors as defined by the ICRP Publication 103 [ICRP, 2013].
Radiation type Weighting factor, wR
Photons 1
Electrons and muons 1
Protons and charged pions 2
Alpha particles, fission fragments and heavy ions 20
Neutrons:













Unlike the equivalent does which does not matter which tissue is being irradiated, effective dose
takes into account the irradiated tissue. ICRP has introduced the effective dose where tissue
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dependent weighting factors have been included [ICRP, 2013].








where wT is the tissue weighting factor in Table 2.3.2 below and its unit is also Sv [ICRP, 2013].
Table 2.3.2: Tissue weighting factors as defined in ICRP Publication 103 [ICRP, 2013].
Organ/tissue Weighting factor, wT
Breast, bone marrow, colon, lung, stomach, remaining tissues* 0.12
Gonads 0.08
Bladder, liver, esophagus, thyroid 0.04
Bone surface, brain, salivary glands, skin 0.01
*Adrenals, extrathoracic region, gall bladder, heart, kidneys, lymphatic nodes, muscle, oral
mucosa, pancreas, prostate, small intestine, spleen, thymus, uterus/cervix.
2.3.2 Cell survival curve and fractionation
The Linear Quadratic Model using the alpha/beta (αβ ) value describes the relationship between
cell killing or cell inactivation, both for tumor as well as normal tissue in relation to prescribed
dose. The dose where both the linear as well as the quadratic component cause the same amount of
killing is called the αβ ratio. In that respect, the higher the
α
β ratio, the more linear the cell survival
curve while the lower the αβ ratio, the more curved the cell survival curve. The
α
β ratio is important
because tissues that have a low αβ are relatively resistant to low doses compared to tissues with a
high αβ . This therefore means that early responding tissues (rapidly proliferating tumors) have a
high αβ ratio of more than 10 Gy while late responding tissues (slowly proliferating tumors) have
a low αβ of around 3-5 Gy [Nina-Sophie Hegemann et al.]. The low
α
β estimates for PCa suggest
a greater sensitivity to increasing fraction size, raising the possibility of dose escalation through
hypofractionation. The αβ for dose limiting organs in prostate radiotherapy is postulated to be
comparatively higher (rectum and bladder; αβ 3 - 5 Gy). This forms the theoretical basis for an
improvement in the therapeutic ratio of radiotherapy with larger fraction sizes, while delivering an
isoeffective dose to the prostate [Linus C.B. et al., 2017].
The motivation behind fractionation in radiotherapy is based on the fact that there is higher
repair-capacity of normal tissue compared to tumor cells, meaning there is an immediate repair of
most radiation-induced sub-lethal lesions in normal tissues between the fractions and thus allowing
a relative tumor-specific therapeutic effect [Fowler J. F. et al., 2010].
The optimal radiation schedule for the curative treatment of prostate cancer is not known [Brenner
D.J., Hall E.J., 1999]. Prostate cancer patients receiving external beam radiation therapy (EBRT)
typically are treated 5 days per week using daily dose of 1.8 - 2.0 Gy over 7 - 8 weeks, to a total
dose of 74 - 79.2 Gy [Zietman A. et al., 2001]. Based on recent data some clinicians have increased
the total dose of radiation by increasing the number of treatment sessions or fractions and it is
now the standard at some centers to treat men for 8 - 10 consecutive weeks [Zelefsky M.J. et al.,
2002]. The dose of 1.8 - 2.0 Gy per fraction in conventional fractionation (CF) is based on the
presumed relative sensitivity of malignant and normal tissue.
2.3.3 Relative Biological Effectiveness (RBE)
Particles , compared to photons , have a greater radiobiological effect and, therefore, greater
potential to damage cancer cells by interacting more densely with tissue, causing higher levels of
ionization per unit length. The dose then rapidly decreases to zero as heavy particles (as opposed
to photons) stop within the body. Therefore, the integral dose with protons is approximately 60%
lower than that of an external beam photon technique. In order to benefit from the extensive
experience from photon treatments, proton therapy prescriptions are based on physical dose times
a factor to account for the difference in biological effect at the same dose when treating with
photons. This is described by the relative biological effectiveness (RBE); the ratio of doses to
reach the same level of effect (i.e. EndpointX) when comparing two radiation modalities, in this
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case, a reference radiation and proton radiation (Equation 6).




The dose in proton therapy is prescribed as Gy[RBE] according to the International Commission
on Radiation Units and Measurements [ICRU 2007] and in this thesis, we shall use only Gy instead
of Gy[RBE] for simplicity. We use Gy[RBE] but we denote it by Gy. So, whenever Gy is used,
we mean Gy[RBE] (the factor 1.1 is already accounted for in the treatment planning system).
Typically, all treatments in proton therapy assume an RBE of 1.1, a value which is primarily based
on animal experiments conducted in the 1970s [Paganetti H., 2015]. However, the RBE varies
depending on a particle’s energy, depth of penetration, dose per fraction and other parameters
[Paganetti H., 2011]. The single value of 1.1 is therefore only a generic value. It has been shown in
in vivo and in vitro studies that the RBE can vary significantly [Paganetti H. et al., 2002], but there
is no clear clinical data that indicates that the use of 1.1 as the generic RBE value is unreasonable
[Paganetti H., 2014]. In addition, there is no clear clinical data that confirms that an RBE of 1.1
is correct [Paganetti H., 2011]. The RBE is closely related to the LET in the sense that the former
increases as the latter increases. At a LET of approximately 100 keVµm−1, the maximum RBE
is about 3-8, depending on the level of cell kill. Beyond this LET value, the RBE declines due to
cell overkill. This is because high LET particles are densely ionizing and will deposit more energy
to the DNA than what is required to kill the cell, thereby decreasing the effectiveness. This effect
is shown in Figure 8 below.
Figure 8: Illustration of the relationship between RBE and the mean LET. [Mayles A. et al., 2007].
2.4 Photon Therapy Techniques
A number of techniques are employed in the delivery of photons for the treatment of cancer. The
delivery is by use of a LINAC which is a device that uses electricity to form a stream of fast-moving
subatomic particles (photons or electrons). This creates high-energy radiation that may be used
to treat cancer.
The LINAC uses microwave technology to accelerate electrons in a part of the accelerator called
the wave guide which allows these electrons to collide with a heavy metal target to produce high-
energy x-rays. These high energy x-rays are then shaped as they exit the machine to conform to
the shape of the tumor and the customized beam is directed to the tumor. The beam is usually
shaped by a multileaf collimator (MLC) that is incorporated into the head of the machine. The
patient lies on a moveable treatment couch and lasers are used to make sure the patient is in the
proper position. The treatment couch can move in many directions including up, down, right, left,
in and out. The beam comes out of a part of the accelerator called a gantry, which can be rotated
around the patient. Radiation can be delivered to the tumor from any angle by rotating the gantry
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and moving the treatment couch. Patients usually receive EBRT in daily treatment sessions over
the course of several weeks. Figure 9 below shows the major components of a LINAC.
Figure 9: Schematic overview of the simulated Varian Trilogy LINAC head [Borges C., 2011].
A LINAC can be used in a number of ways to carryout the treatment as discussed below:
2.4.1 Three-dimensional conformal radiation therapy (3D-CRT)
Here treatment is achieved by conforming the shape and size of the beam from the LINAC by
the MLCs to that of the tumor/target volume. It is therefore challenging when the target volume
is complex/non-uniformly shaped and is near to or wrapped around an organ at risk (OAR).
This makes it difficult to conform the dose to this shape resulting into the portion of the OAR
immediately surrounding the target to receive high dose. A solution to this could be to use a series
of sequential phases which enables delivery of high dose to the primary site and a lower dose to
areas close to OAR [James A.P., 1999].
2.4.2 Intensity Modulated Radiotherapy (IMRT)
IMRT works by varying the dose intensity across the beam and this enables tailoring of the dose
distribution more precisely to the shape of the target. Intensity across the beam is achieved by
using the multileaf collimators (MLCs), which move into different positions throughout the delivery
of the beam, shielding some areas within the field more than others. This can be done by dynamic
motion of the MLCs where the MLCs move across the beam at different speeds to build up areas
of low and high intensity or step and shoot motion where each beam angle consists of sub-fields
which are delivered sequentially. In the stop and shoot, The machine is only switched on for each
sub-field once the MLCs are in the correct position, and switched off and the leaves will move to
the next position [Craig E., 2011].
2.4.3 Volumetric Arc Radiotherapy(VMAT)
Variation of IMRT is called VMAT and LINAC is used as it delivers the radiation quickly when
the gantry rotates once around the body and the treatment is given over just a few minutes. In
VMAT, there are no set beam angles, the intensity modulated beam is deliverd as the gantry arcs
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around the patient, that is the beam is dynamically delivered. The gantry speed adds a further
dynamic component that can be used to control the intensity of the beam as needed [Erminia I.,
2015].
2.5 Proton Therapy Techniques
Protons can be generated/delivered by a special machine called a cyclotron or synchrotron. This
machine costs millions of dollars and requires experts to use and maintain it. Because of this,
proton beam therapy is expensive, and very few treatment centers in the United States, Germany,
Sweden, but many countries are currently building new facilities (Netherlands, Denmark, etc). In
order to achieve the prescribed dose to the prescribed area, different types of equipment are used
to direct and shape the beam. A monoenergetic beam from the accelerator is unsuitable for cancer
treatment due to its longitudinally narrow Bragg peak. In order to cover the target volume in its
full depth, beams of decreasing energy, and typically decreasing weight, are combined to create
the spread-out Bragg peak (Figure 5). This can be done either actively or passively [Paganetti H.,
2011].
(a) Active modulation
Active modulation is only possible for synchrotrons. This involves the direct change of the energy
of the beam within the accelerator and the energy change must happen quickly in order to limit the
treatment duration and to allow for fast switching between treatment rooms. The energy selection
must also be accurate in order to determine the depth of the Bragg peak with sufficient accuracy
[Paganetti H., 2011].
(b)Passive modulation
Passive modulation is used for cyclotrons only. This is because these accelerators only work at a
specific energy. Passive modulation is achieved by inserting material in front of the beam, thereby
decreasing the effective energy, and thus the range of the particles. This can either be done im-
mediately after the beam has been extracted from the cyclotron, or the modulation can take place
directly inside the treatment nozzle [Paganetti H., 2011]. To create the SOBP, either a plate with
ripples (ridge filter) or a rotating wheel with varying thickness in the azimuthal direction (modu-
lator wheel) is used. The modulators are designed such that the result is a predefined depth dose
profile.
2.5.1 Beam delivery
Both longitudinal and lateral dose spread over the target is required during the course of beam
delivery which can be done by different beam delivery techniques. There are two major delivery
techniques in particle therapy: beam scanning (active beam shaping) and beam scattering (passive
beam shaping) [Schulz-Ertner D. et al., 2006].
(a)Passive scattering
This was the first method to be developed. In this delivery technique, the narrow particle beam is
spread in the lateral direction either by using one scatter foil (single scattering technique), when
small fields are requested, or two scatter foils (double scattering technique), when a broader beam
is preferable [Schippers J. M., 2009]. The beam must additionally be shaped according to the tar-
get volume. Collimators are used to adapt the field for each separate treatment angle [Paganetti
H., 2011]. Figure 10 shows passive scattering.
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Figure 10: Illustration of passive scattering [Carolyn V., 2015].
The main advantage of passive scattering is that the change of energy between the different layers
is achieved much faster than the scanning technique. Since the whole field is delivered almost
at once, the complete treatment duration will also be shorter [Engelsman M., 2013]. However,
in passive scattering technique, subsidiary dose to the patient may occur due to the additional
collimation material in the beam line and this can lead to more nuclear fragments [Paganetti H.,
2011].
2.5.2 Scanning beam
Pencil beam scanning uses magnets to deflect, focus and steer the charged particles in the beam.
The magnets consist of two dipoles, run by fast power suppliers; one for horizontal steering and
one for vertical steering. This way a narrow beam can be used to ”paint” the dose over the target,
layer by layer. When one layer of voxels has been irradiated, the energy of the beam is decreased,
and a new layer can be treated [Grupen C. et al., 2011]. The voxels, or spots, can be irradiated one
by one (discrete spot scanning) meaning that the beam is turned off between the irradiation of each
spot. Another method is the raster scanning technique where the beam continuously irradiates
while the dipoles are simultaneously steering the beam [Schippers J. M., 2009]. In pencil beam
scanning, it is highly important that beam intensities and beam positions are monitored in order
to ensure a safe and accurate delivery of the dose to the patient [Schlegel W.C. et al, 2006]. The
main advantage of pencil beam scanning is that it has a high dose conformity compared to the
passive scattering technique, and hence, lower doses to healthy tissues may be achieved. There will
also be no additional dose due to nuclear fragmentation from beam shaping materials [Paganetti
H., 2011]. The method of pencil beam scanning is shown in Figure 11 below.
Figure 11: Illustration of pencil beam scanning [Paganetti H., 2011].
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Proton pencil beams relies on the charged-particle Bragg peak.This means the use of characteristic
peak of dose at the end of range together with the modulation of pencil beam variables to create
target-local modulations in dose that achieves the dose objectives. IMPT makes better the X-
ray intensity modulated beams (intensity modulated radiotherapy or volumetric modulated arc
therapy) with dose modulation along the beam axis and also lateral, in-field, dose modulation.
IMPT is therefore the electromagnetic spatial control of well-circumscribed pencil beams of protons
of variable energy and intensity. It has an disadvantage that the treatment takes longer than with
passive scatter.
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Chapter 3: Treatment planning and strategies for treatment
delivery
3.1 Patient model
In the process of image acquisition using any modality such as CT, MRI to be used in the treatment
planning system (TPS) there has to be a reproducible patient positioning. These images are used
to define and display contours and surfaces for normal and critical structures. Registration of all
input data, including registration with initial simulation contours, films, patient position, etc are
then done to enable define target contours, generate 3D target surface using surface expansion,
import target information from multiple imaging modalities. This is then followed by determining
beam or source arrangements, generating beam’s-eye-view displays. If need be design of field
shape using blocks, MLC; determine beam modifiers using compensators, wedges and determine
beam or source weighting. With all these in place then selection of dose calculation algorithm and
methodology, calculation grid and window, etc are done and sequentially dose calculations, relative
and absolute dose normalizations and input of the dose prescription. To estimate dose, Hounsfield
units (HU) are converted to electron density/stopping potential and that is why HU is a common
unit used to express CT numbers in a standardised and convenient form in CT.
3.2 Geometrical uncertainties
High geometrical accuracy is a prerequisite for a safe clinical application of conformal RT [Marcel
Van Herk, 2004]. However, treatment optimization is limited by variation in delivered dose caused
by errors in patient treatment positioning and interfractional variation of organ position, size, and
shape.
An error in photon and proton therapy refers to any deviation between planned and delivered
dose. There are two types of errors that are encountered; random and systematic errors. Random
errors are treatment execution errors and influence each fraction individually while, systematic
errors are treatment preparation errors and influence all fractions.
There are a number of causes of these errors at the treatment planning stage; for instance, mo-
tion of skin with respect to the internal anatomy which limits the reproducibility hence introducing
a systematic setup error. The tumor is imaged in an arbitrary position which leads to a systematic
error and this may further lead to the image being distorted because of the interference of the
scanning process and organ motion. Delineation during treatment planning is also another process
that may introduce systematic error. Random errors also occur during treatment and these errors
are mostly due to setup error and organ motion. In this study, motion uncertainity is of interest
and motion can be divided into inter- and intrafractional movements. Interfractional movements
are variations occurring between two different fractions e.g, due to daily variation in filling of the
bladder and rectum. Intrafractional movements happen within a treatment session, e.g, due to
breathing, bowel gas, or small patient movements. These movements result into setup error which
has both a systematic and a random component. For instance, motion of skin with respect to the
internal anatomy limits the reproducibility of the patient setup on the CT scanner, introducing a
systematic setup error. Variations in daily setup may affect the target coverage [Zhang X. et al.,
2007, Yoon M. et al., 2008, Sejpal SV. et al., 2009].
3.3 Methods to account for motion uncertainties in delivery
The patient is fitted with immobilisation device such as knee cushion, feet board to keep the
body part to be treated still during treatment. At the beginning of the treatment session, the
therapist positions the patient on the treatment table, guided by the marks on the skin defining
the treatment area. If molded devices were made, they will be used to help the patient maintain
the proper position. The patient may be repositioned during the procedure. Imaging systems on
the treatment machine such as x-ray or CT may be used to check positioning and marker location.
3.3.1 Estimation of margins to account for motion
Systematic and random errors have different significant dosimetrical impacts, and should be treated
differently in margin calculations [Stroom J.C. et al., 2002]. This means that random and system-
atic errors, Σpop and Σpop should not be added in quadrature to determine the margin.
CTV to PTV margin (M) recipe that properly accounts for the different consequences of systematic
and random errors were proposed in 1999 [Stroom J.C.et al, 1999]. Basing on the calculation of
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DVHs, it was found that M = 2Σpop + 0.7σpop ensured adequate coverage of CTV. The assumption
for the derivation of the recipe was that, on average, 99% of the CTV should at least get 95% of
the dose which was derived from ICRU criterion [Stroom J.C.et al, 2002]. M = 2Σpop was used for
systematic error and the average DVH represented each patient’s situation fairly well with only a
small inter-patient variation [Stroom J.C.et al, 2002].
Using average histograms of similar type (minimum dose-population histograms), a similar margin
by Stroom et al. was proposed, M = 2.5Σpop + 0.7σpop [Van Herk et al., 2000]. The assumption
for the recipe was that for 90% of the patients, the minimum dose should be at least 95%.
3.3.2 Image-guided radiation therapy (IGRT)
There is no standardized or consensus definition of IGRT. It has been rather malleable and author
dependent, meaning different things to different people [Gupta T. and Anand N.C, 2012]. Some
define it very broadly i.e., use of imaging for detection and diagnosis; delineation of target volumes
and organs-at-risk (OARs); determining biological attributes such as size, shape and position of
the tumor; dose distribution design; dose delivery verification and assurance; and deciphering
treatment response [Reco C. et al., 2008]. A more focused and accepted definition of IGRT is
use of frequent imaging within the radiation treatment room, with decisions based on imaging to
improve precision of radiation therapy delivery i.e., process of in-room imaging guiding radiation
delivery [Verellen D. et al., 2008, Dawson L.A. et al., 2007]. Imaging includes but may not be
limited to planar imaging, cine-imaging, volumetric imaging and surface-tracking [Gupta T. and
Anand N.C, 2012].
3.3.3 Adaptive Radiation (Proton) Therapy (ART or APT)
Adaptive radiotherapy is defined as changing the original radiation treatment plan (by modifying
either beam apertures or intensity patterns) during a course of fractionated radiotherapy to account
for the temporal changes in anatomy (weight loss, tumor shrinkage, internal organ motion) or
changes in tumor biology or function (hypoxia, proliferation) [Yan D. et al., 2010]. It aims to
adapt to the change in patient contour or tumor volume by modification of the dose prescription,
target volumes, and/or the treatment plan. A novel method of adaptive planning is to make
multiple plans for predictable change in the shape and size of target volumes with treatment being
executed with the ’plan of the day’ that most fits the changing anatomy [Gupta T. et al., 2012].
Adaptive radiotherapy has been introduced to either reduce or compensate for the effect of
patient-specific treatment variation measured during the course of radiotherapy. Adaptive radio-
therapy help to manage an individual’s treatment by, including patient-specific treatment variation
identified and quantified during the course of radiotherapy in the treatment planning and deliv-
ering optimization. The importance of using an adaptive process in radiation therapy is that
the treatment plan, especially the margin and treatment dose, can eventually be customized to
the individual patient. Studies have demonstrated that adaptive radiotherapy could significantly
improve the therapeutic ratio by safely reducing the large target margin that has to be used in con-
ventional radiotherapy for prostate cancer treatment [Michel G. et al., 2010]. Clinical application
of off-line image-guided adaptive radiotherapy for prostate cancer has demonstrated encouraging
clinical outcome [Michel G. et al., 2010]. Long-term clinical follow-up has shown significant im-
provement in terms of tumor control and low toxicity profile, emphasizing the beneficial effect
of image-guidance and adaptive treatment [Michel G. et al., 2010]. Continuous development in
adaptive radiotherapy has made possible additional increases in target dose by further reducing
target margin when using on-line image-guided adaptive intensity-modulated radiation therapy.
3.3.4 Definition of target volumes
Different volumes related to both the tumor and the normal tissues are defined for use in the treat-
ment planning and evaluation processes. These different volumes are delineated in the planning
process and are used for prescription, recording and reporting doses to the target volumes and
volumes of normal tissues at risk [ICRU report 83, 2010]. These volumes include: gross tumor
volume (GTV), the clinical target volume (CTV), the planning target volume (PTV), organ at
risk (OAR), planning organ at risk volume (PRV), internal target volume (ITV), treated volume
(TV) and remaining volume at risk (RVR). The important volumes that will be referred to for the
purpose of this study are; CTV, PTV and OAR.
(a) Gross tumor volume (GTV)
GTV refers to the gross demonstrable extent and location of the tumor. The GTV may comprise
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of a primary tumor (primary tumor GTV or GTV-T), metastatic regional node(s) (nodal GTV or
GTV-N), or distant metastasis (metastatic GTV or GTV-M).
GTV needs to be described and reported completely and accurately for a number of reasons;
Firstly, GTV is a requirement in staging of the tumor. Secondly, to obtain a local tumor control,
an adequate absorbed dose must be delivered to the whole GTV. The third reason is that, the
evaluation of the regression of the GTV might be needed for redefining the CTV and the PTV
during the course of treatment. Fourthly, changes of GTV during treatment might be predictive
of treatment outcome [ICRU report 83, 2010].
(b) Clinical target volume (CTV)
The CTV is a volume of tissue that contains a demonstrable GTV and/or subclinical malignant
disease with a certain probability of occurrence considered relevant for therapy. There is no gen-
eral consensus on what probability is considered relevant for therapy, but typically a probability
of occult disease higher than from 5% to 10% is assumed to require treatment [ICRU report 83,
2010]. The selection of the tissues that bear risk for microscopic infiltration outside of the GTV
is a probabilistic assessment integrating the biological and clinical behavior of the various tumor
entities and the knowledge of the surrounding anatomy, including structures that are barriers to
tissue infiltration (e.g., muscular fascia, bone cortex), or on the contrary - structures that are easy
conduits for tumor dissemination (e.g., fatty space). Different tumors can exhibit a variety of
spread patterns [ICRU report 83, 2010].
(d) Planning target volume (PTV)
The PTV is a geometrical concept introduced for treatment planning and evaluation. It is the
recommended tool to shape absorbed-dose distributions to ensure that the prescribed absorbed
dose will actually be delivered to all parts of the CTV with a clinically acceptable probability,
despite geometrical uncertainties such as organ motion and setup variations. It is also used for
absorbed-dose prescription and reporting. It surrounds the representation of the CTV with a mar-
gin such that the planned absorbed dose is delivered to the CTV [ICRU report 83, 2010].
(e) Organ at risk (OAR)
The OAR or critical normal structures are tissues that if irradiated could suffer significant mor-
bidity and thus might influence the treatment planning and/or the absorbed-dose prescription.
In principle, all non-target tissues could be OARs. However, normal tissues considered as OARs
typically depend on the location of the CTV and/or the prescribed absorbed dose. For example,
in the post-operative irradiation of a lower-limb soft-tissue sarcoma, the muscles that are not in-
cluded in the compartment at risk for microscopic infiltration are considered as OARs, and thus
will influence the beam delivery [ICRU report 83, 2010].
(f) Planning Organ at Risk Volume (PRV)
Just like in the case of the PTV, uncertainties and variations in the position of the OAR during
treatment must be considered to avoid serious complications. This therefore means margins have
to be added to the OARs to compensate for these uncertainties and variations, using similar prin-
ciples as for the PTV. This leads, in analogy with the PTV, to the concept of PRV [ICRU report
83, 2010].
3.3.5 Treatment planning
Dose volume histograms (DVHs) are a simple way to evaluate the dose distribution on volumes
of interest. Cumulative DVHs, showing the amount of dose up to a given value received by a
fraction of the total volume, are the most common type of dose volume histograms. The DVHs
can employ both relative and absolute doses and volumes. By using DVHs for plan assessment
and comparison, the spatial information is lost. This loss of spatial information can, however, be
compensated for by using dose distribution displays in conjunction with the DVHs [Li Z., 2009].
Absorbed dose is used in the formulation of objective functions in optimization systems. Although
dose volume histogram (DVH) - objectives are notoriously difficult to handle in the optimization
process [Clark V. H. et al., 2008], progress towards an efficient reformulation of the problem has
been made [Zarepisheh et al., 2013]. Since DVHs are widely used for clinical assessment of dose
plans, they would have an immediate effect both on treatment plan optimization and quality as-
surance, if it is possible to predict what DVHs are achievable.
The method of inverse planning is typically used for intensity-modulated particle therapy
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(IMPT). IMPT in pencil beam scanning means that the scanning magnets can steer the pen-
cil beam and conform the dose in the transverse plane. Dose conformation in this plane is also
achievable for photons by IMRT or VMAT. However, due to the Bragg peak of protons, an addi-
tional degree of freedom is introduced, meaning that modulation along the beam axis is possible.
In IMPT, each pencil beam must be weighted relative to each other and must be optimized sep-
arately [ICRU report 78, 2009]. The optimization process is an important part of the treatment
planning. Optimization is essentially to iteratively generate, followed by automatically assessing,
a large number of plans and choosing the best among them. A computer is given constraints and
objectives on targets and organs at risk by a clinician. If given constraints, the computer must
follow these without violation. Objectives, on the other hand, are typically given weights relative
to each other, in which case a small violation may be allowed. An example of objectives can typi-
cally be 51Gy to 0% of the tumor volume, while no more than 49Gy should be received by 100%
of a nearby OAR. When the computer have calculated the best plan for the given constraints, it
should be inspected by the treatment planner. If the results are unsatisfactory, the objectives and
constraints can be edited and a re-optimisation can be done.
3.4 Plan evaluation-DVH and how evaluation criteria has been derived
A treatment plan is evaluated by several different methods. Usually, dosimetrics and volumet-
rics are inspected using dose distributions displayed onto patient CT scans, and graphically using
DVHs alongside predetermined dose constraints to target volumes and organs at risk [Li Z., 2009].
Objective functions are commonly used in radiotherapy to measure treatment plan quality and
can be classified into physical, e.g., the minimum/maximum dose and mean dose, and radiobio-
logical, e.g., the equivalent uniform dose (EUD), tumor control probability (TCP), normal tissue
complication probability (NTCP) and logarithmic tumor control probability (LTCP). The first
class typically measures deviations from a prescribed dose level in an organ, while the second class
attempts to model the radiobiological effects of irradiating the organ.
3.5 Robust evaluation
Target coverage should generally not be compromised to reduce the normal tissue risks when doing
plan evaluation. The quality of a treatment plan is evaluated in several ways by looking at outcomes
of treatment quantities such as DVH parameters, tumor control probability (TCP) and normal
tissue complication probability (NTCP) or equivalent uniform dose (EUD) [Niemierko A., 1999].
Due to the non-uniform nature of dose distributions throughout organs or volumes, it is always
difficult to report the doses by use of some parameters like dose volume distributions/histograms
(DVD/DVH). Equivalent uniform dose (EUD) is used for reporting and quantitatively compare
in-homogeneous dose distributions. EUD is the dose (in Gy), which, when distributed uniformly
across the target volume, causes the survival of the same number of clonogens [Niemierko A., 1997].
Range uncertainties are simulated by recalculating the treatment plans on a repeat CT scan
where all CT numbers are systematically increased or decreased by a given percentage of its value,
as proposed by Lomax et al. [Lomax et al., 2008]. Setup uncertainties can be simulated by an
online patient setup correction protocol with bony anatomy as reference. Ideally, setup errors are
zero after applying online corrections. But not all errors are eliminated for instance, errors from
intrafractional motion or uncorrected deformations of the bony structures [Van Kranen S., 2009].
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Chapter 4: Project aim and motivation
The aim of this project is to construct a plan library of the lymph nodes with prostate at different
positions to help investigate if the construction of a plan library for prostate cancer patients can
result in improvement of dose to the tumor while reducing the doses to the surrounding normal
tissues and OARs. The involvement of three target structures; prostate, seminal vesicles and lymph
nodes; and the independent motion of these structures make delivery of the treatment with protons
challenging and therefore use of plan library could improve on the dose on the target while sparing
the normal tissues.
A plan library approach has been employed in one previous study for photons [Xia P. et al.,
2010], but this thesis will extend it to proton therapy. Due to the nature of how proton deposits its
energy, we think that by establishing the appropriate margins and using appropriate plan-of-the
day, this strategy will lead to improved doses to the targets and reduced doses to the OARs near
the targets. Furthermore, this method could be one of the simple feasible methods as we shall have
only one planning CT (pCT) per patient and no delineation of the target volumes is required for
every treatment session. As mentioned earlier, RT of prostate is challenging as there are internal
target and organ motion during treatment. To limit range uncertainties, we shall employ bony
anatomy setup in this study basing on a study conducted by Thönqvist S. et al. which showed that
bony anatomy setup was slightly better compared to positioning using fiducial markers [Thönqvist
S. et al., 2013]. The plan library will be limited to three plans in addition to one conservative plan
with larger margins and this will allow feasibility for manual selection otherwise manual selection
will become difficult with large number of plans. Finally, the plan library construction will be
based on a population analysis of prostate motion relative to bony anatomy, and thus will require
only a single pCT for every patient.
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Chapter 5: Method and materials
This chapter gives the details of the method and materials employed in this master project for
two studies A and B. Study design, patient selection, patient material and how the studies were
carried out will be described including the variables considered as well as the analysis.
5.1 Study design
The study was designed as a quasi-experimental retrospective study using acquired image infor-
mation of patients previously treated at Haukeland University Hospital. The study was focused on
method-development for treatment of locally advanced prostate cancer with intensity-modulated
proton therapy (IMPT) and compared two different treatment options by in-silico simulation of
delivered dose based on repeat imaging (CT) data of each individual patient.
The study was divided in two phases:
(A) An initial analysis of prostate target motion relative to bony anatomy and;
(B) Comparison of two different treatment options. The results from the initial analysis (A) were
used as input for (B).
5.2 Patient selection
The patients selected for inclusion in this study had a number of criteria that were fulfilled as
mentioned below. All these patients;
• had locally advanced T2-T4 prostate cancer, Nx-1, M0, PSA > 10 and Gleason score > 7.
• had fiducial gold markers implanted into the prostate gland.
• were treated during 2007/2008 at Haukeland University Hospital as a part of a phase II dose-
escalation trial (REK approval 2006 -15727 IMRT basert integrert boost ved lokalavansert
cancer prostate En fase II studie).
• had repeat CT (rCT) scans acquired twice a week during the course of treatment for the
purpose of studying organ motion and development of new treatment techniques for com-
pensation of geometrical uncertainties.
• had signed written consent for participation in the study including acquisition of rCT scans.
Eighteen (18) patients meeting the inclusion criteria were used in the initial analysis, A of inter-
fractional prostate target motion relative to bony anatomy. Five (5) independent patients meeting
the inclusion criteria and not included in the initial analysis were then used for comparison of the
two different treatment options B. These patients furthermore had CTVs and OARs contoured
and quality checked by an independent observer on all rCTs.
The number of patients was chosen as a trade-off between sufficient data for statistical analysis
and manageable workload within the time frame of the master thesis project.
5.3 Patient material
For the selected patients, CT images had been acquired and volumes contoured as described in the
following sections.
5.3.1 CT scanning
All the twenty three (23) patients had undergone CT imaging. The planning CTs (pCTs) were
acquired with bladder contrast while the rCTs were acquired without bladder contrast but with
same protocol as in the pCT acquisition. The rCTs were acquired twice a week during the course of
treatment, as close to the treatment session as practically as was possible. All CTs were acquired
with knee and ankle fixation in place in the head-first-supine position and covered L3/L4 to anus.
Before the acquisition of the pCT, no laxatives were given to the patients but they were asked to
empty their bowels before the pCT was taken. A total of 225 CTs from the twenty three patients
were obtained with each patient having one pCT and a range of 6 - 10 rCTS.
5.3.2 Gold marker (GM) based registrations
For each patient, each of the rCTs had been registered to the pCT based on the fiducial gold
markers (GM) implanted into the prostate. This had been performed by a medical physicist in
Eclipse Treatment Planning System (Varian Medical Systems, Palo Alto, CA, USA) uisng a manual
procedure allowing for translational shifts only.
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5.3.3 Contouring
Manual contouring had been employed for all the three different targets. The manual contouring on
pCTs and all the rCTs were done in Eclipse Treatment Planning System (Varian Medical Systems,
Palo Alto, CA, USA). The delineation was such that CTV67.5 was defined as the prostate gland
including the capsule as well as tumor extension outside the prostate gland, CTV60 overlapped
with CTV67.5 and also included the seminal vesicles and CTV50 was defined as CTV60 and the
pelvic lymph nodes contoured according to the Radiotherapy Oncology Group (RTOG) guidelines
but omitting the pre-sacral nodes. All these target volumes had been contoured by the same
experienced oncologist.
Other organs contoured included the rectum which was defined from the recto-sigmoid flexure
to the anal verge including content and the bladder which was defined from apex to dome including
content. The contouring of both the rectum and the bladder on all CT scans for all patients had
been done by a single medical physicist. Large bowel was contoured from the recto-sigmoid flexure
and up to L3/L4 and small bowel was contoured as the remaining bowel loops and this had been
done by a single medical physicist. Quality assurance of all the contouring had been done by an
independent medical physicist.
5.4 Registration on bony anatomy (BA)
Registration of the rCTs to the pCT was performed for each individual patient (23 patients in
total) to mimic image-guided patient positioning based on bony anatomy. This was performed by
the candidate using the image registration software implemented in Eclipse TPS (Varian Medical
Systems, Palo Alto, CA, USA). The registrations were restricted to rigid translational shifts in the
Right-Left (x), Anterior-Posterior (y) and Caudal-Cranial (z) directions and performed according
to procedure (Appendix A). Automatic registration was employed here, but a coarse manual reg-
istration was performed beforehand to roughly align the CT datasets. Subsequently, a volume of
interest (the registration box) was placed around the pelvic bones including the prostate to restrict
the registration area. Finally, the result of the automatic registration was visually reviewed to ex-
clude obviously inaccurate registrations and re-registrations were done for the inaccurate ones.
Accurate registration is one where visual inspections reveal that the rCT is lying exactly on top of
the pCT as explained in Appendix A.
5.5 Study A: Prostate target motion relative to bony anatomy
5.5.1 Aim
The aim of this study was to determine the degree of interfractional prostate motion relative to
bony anatomy which will then be used to calculate population based margins to be used as margins
to create PTVs for study B and hence the input for constructing a plan library.
5.5.2 Variables
The x-, y- and z-coordinate vectors of the registrations based on both the GM and BA were recorded
in millimeters (mm) . These registration coordinate vectors were based on DICOM/Eclipse coordi-
nate system and were used to calculate the magnitudes and directions of the shifts of the prostate
in the respective directions for each rCT for all the 18 patients as illustrated in Figures 12 and 13
below.
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Figure 12: Eclipse coordinate system with the patient lying in ”head-first-supine” position.
x - from right to left (RL)
y - from anterior to posterior (AP)
z - from caudal to cranial (CC).
Figure 13: Illustration of registration vectors and how the shift, ~GB was calculated from gold
marker-based ( ~GM) and bony anatomy-based ( ~BA) registration vectors.
The shift between gold marker-based registration and bony anatomy-based registration was calcu-
lated as;
~GB(∆x,∆y,∆z) = ~GM(x, y, z)− ~BA(x′, y′, z′), (7)
where ~GM(x, y, z) was the GM based registration coordinate vector, ~BA(x′, y′, z′) was the BA
based registration coordinate vector and ~GB(∆x,∆y,∆z) were the shifts in the respective direc-
tions.
~GB(∆x,∆y,∆z) was calculated for each patient j (j ∈ [1, N ]) and each rCT i (i ∈ [1,K]); and
was used to calculate the systematic error for patient j, µj(∆x) in x (∆x ), µj(∆y) in y (∆y) and







µj(∆y) and µj(∆z) were calculated the same way.
~GB(∆x,∆y,∆z) was also used to calculate the random error for patient j, SDj(∆x) in x (∆x ),










SDj(∆x) was the standard deviation in ∆x for the j
th patient, K was the total number of rCTs
for the jth patient and i ∈ [1,K]; and SDj(∆y) and SDj(∆z) were calculated the same way.
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The patient-specific systematic (µj) and random (SDj) errors were then used for determining the
standard deviations of systematic errors, Σpop and standard deviations of random errors, σpop for
the population in all the motion directions. The calculation of Σpop and σpop were based on Van
Herk’s method for determining errors and margins in radiotherapy [Van Herk, 2004], where
















j is the jth patient of the N patients in the x direction and the same was done for y and z directions.










where j is the jth patient of the N patients and SDj(∆x) is the standard deviation of the j
th
patient in x direction. The same was done for y and z directions.
5.5.3 Research questions and analysis
(1) How large is interfractional prostate motion relative to bony anatomy?
Interfractional prostate motion occured in Right-Left (x), Posterior-Anterior (y) and Caudal-
Cranial (z) directions. Therefore, each of these directional shift gave the magnitude of the shift
for every treatment session. This was done by determining µj and SDj for all the three directional
motions.
(2) Is there a correlation in motion directions?
Motion in one direction may affect another directional motion. Calculations of correlation coeffi-
cients, ρ̂ between any two directions (x and y, x and z; and y and z) of motion were done using





























and Kpop is the total number of rCTs for all the patients. ρ̂∆x∆z and ρ̂∆y∆z were calculated the
same way.
Scatter plots (x versus y, x versus z and y versus z) were also made and both the calculations
and scatter plots helped in ascertaining the correlations between the directions.
(3) What are the proper PTV margins to account for prostate motion when positioning on bony
anatomy?
Calculation of the standard deviation of the mean shifts of the population, Σpop and the root
mean square of SDj , σpop gave the variables used in the determination of the PTV margins. The
direction specific margins; M∆x, M∆y and M∆z in the directions x, y and z were then calculated
basing on Van Herk formula for errors and margins which works on assumption that 90% of the
patient population should receive the minimum dose to the CTV of 95% of the nominal dose (i.e.,
the dose at the specification point) or higher [Van Herk, 2000]. The margin was calculated as;
M = 2.5Σpop + 0.7σpop (17)
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(4)Which prostate shifts would be appropriate for constructing plan library out of the 3 plans and
a conservative plan?
The selection of prostate shifts for construction of a plan library was done basing on the positions of
prostate for a shift of +/-1.5SD of the systematic error. The prostate and seminal vesicle positions
were chosen basing on directions that had the greatest interfractional motion and directional motion
correlations.
5.6 Study B: Comparison of standard treatment with adaptive proton
therapy
5.6.1 Aim
To compare standard whole pelvic treatment of high-risk prostate cancer with IMPT to a plan-of-
the-day IMPT approach.
5.6.2 Hypothesis
We hypothesize that the treatment approaches give equal minimum dose to the CTVs, but reduced
doses (gEUD) to the rectum and bladder with the plan-of-the-day approach.
5.6.3 General-treatment planning
Treatment planning was carried out by the student which involved creating the PTVs by expanding
the CTVs. A number of structures were created in both strategies to help in the optimization
process and these included PTV50Left, PTV50Right, help volume for PTV50. Other structures
created included normal tissues which had a margin of 4cm except 1cm in the cranial-caudal
direction around PTV50, cropped 5mm towards PTV50 and PTV60 and also 1.5cm towards the
body; rectumout to minimise doses to the rectum and this was cropped 5mm towards PTV60;
bladderout to minimise doses to the bladder and was cropped 5mm towards PTV60 and PTV50
and Under67.5 with a margin of 2cm around PTV67.5 to ensure there was no overlap between
PTV60 and PTV67.5. After creating all the necessary structures, optimization was done where
objectives (Table 5.6.1) were set for helpPTV50, PTV60, PTV67.5, normal tissues, rectum and
Under67.5 and dose calculations were then carried out. All prescriptions and doses are given in
Gy [RBE], that is, photon dose of 1.1.
Table 5.6.1: Objectives used in optimization.
Structure Volume [%] Upper dose [Gy] Lower dose [Gy] Priority
PTV50Help Upper 0.0 51.0 120
Lower 100.0 49.0 120
PTV60 Upper 0.0 68.0 100
Upper 36.9 63.4 80
Lower 100.0 59.0 120
PTV67.5 Upper 0.0 68.5 120
Lower 100.0 66.5 120
Normal Tissue Upper 0.0 47.0 100
Rectumout Upper 0.0 45.0 100
Under67.5 Upper 0.0 61.0 80
No spot smoothing was employed but a spot smoothing radius of 2cm was used. All the structures
were created following procedures in Appendix B (Procedure for creating structures in conservative
treatment planning) and Appendix C (Procedure for creating structures for plan library treatment
planning). The Eclipse treatment planning system (Varian Medical Systems, Palo Alto, USA) was
used for generating all IMPT plans and dose re-calculations. All IMPT plans used two lateral
opposing fields ( 90◦ and 270◦ ) as shown in Figure 14 below.
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Figure 14: Beam set up for the IMPT (two lateral opposing fields).
5.6.4 Standard treatment
Margins
Results from study A were used to choose margins for the prostate. In the standard treatment
planning, an isotropic margin of 5mm [Thörnqvist et al., 2013] was used to create PTV50 around
CTV50, a 3mm margin in the left-right and 10mm margins in the cranial-caudal and anterior-
posterior and a margin of 5mm in the left-right and 10mm margins in both the cranial-caudal
and anterior-posterior were used to create PTV67.5 around CTV67.5 and PTV60 around CTV60
respectively.
Re-calculation of plans on rCTs
The simulation of the proton delivery was done by transferring the plans to each of the rCTs which
used rigid registrations based on bony anatomy. The dose distribution for each of the rCT scans
was then re-calculated to account for the differences in patient anatomy such as target/organ mo-
tion and deformations; and heterogeneities. All these plans were then checked for specified criteria
by an independent observer (the supervisor).
5.6.5 Adaptive proton therapy
Margins
A 5mm isotropic margin was used, basing on Thönqvist et al. treatment simulations with a statisti-
cal deformable motion model to evaluate margins for multiple targets in radiotherapy for high-risk
prostate cancer [Thönqvist S. et al., 2013], for creating PTV67.5, PTV60 and PTV50 while the
rest of the other structures were created the same way as in standard/conservative strategy.
Plan library
The plan library for this study was based on three different positions of the PTV67.5 + PTV60
with the position of the lymph node kept constant. Due to correlation in the anterior-posterior
(AP) and cranial-caudal (CC) directions (Study A), the library consisted of three (3) PTV67.5
+ PTV60-CTVs: 2 PTV67.5 + PTV60-CTVs shifted +/- 1.5 SD of the systematic error in AP
(+/- 5.0mm) and CC (+/-4.6mm) direction and 1 PTV67.5 + PTV60-CTV without shift. The
positions are as shown in Figures 15 to 18 below.
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Figure 15: Different positions of the prostate with the corresponding PTVs.
Figure 16: Position of lymph nodes relative to the shifted positions of prostate in CC direction.
Figure 17: Position of lymph nodes relative to the shifted positions of prostate in RL direction.
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Figure 18: Position of lymph nodes relative to the shifted positions of prostate in AP direction.
For each PTV position, a new treatment plan was created as shown in Table 5.6.2 below.
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Table 5.6.2: Plan library selection.
Patient rCT Plan selected for PL
1 1 Conservative plan
2 Conservative plan






9 Shifted position (-AP, -CC)





6 Shifted position (+AP, +CC)
7 Shifted position (+AP, +CC)
8 Conservative plan
9 No shift
3 1 No shift
2 No shift
3 Shifted position (+AP, +CC)
4 Shifted position (+AP, +CC)
5 Shifted position (+AP, +CC)
6 No shift
7 Shifted position (+AP, +CC)
8 No shift






7 Shifted position (-AP, -CC)
8 Conservative plan





6 Shifted position (-AP, -CC)
7 Shifted position (-AP, -CC)
8 Shifted position (-AP, -CC)
9 Shifted position (-AP, -CC)
Plan selection and re-calculation of plans
After the plans with prostate in different positions were created, plan selection for the library
was then done by the student and verified by the supervisor. These plans were selected by visual
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inspection where plans that fit best were evaluated the pCT are chosen according to procedure in
appendix D. Bascically, the coverage of rCTV67.5 by the different pPTV67.5 were evaluated.
5.6.6 Variables
For the three targets; CTV67.5, CTV60 and CTV50, D98% was used to evaluate minimum dose.
gEUD for the rectum and bladder were also evaluated. D98% and the gEUDs were extracted by
in-house python script provided by the supervisor. The gEUD for the rectum and bladder were























where {vi, Di} are bins of the histogram and ”a” is a tissue specific parameter.
In this study, we will use:
k = 12 for rectum,
k = 8 for bladder,
k = 4 for large bowel,
k = 4 for small bowel,
k = 1 is average dose and
k = ∞ is maximum dose.
5.6.7 Analysis
Plots for D98% for CTV67.5, CTV60 and CTV50 were made for the different treatment sessions
for each patient for both the standard and plan library strategies. A t-test was also done between
standard and plan library treatment approaches using all rCTs for all the CTVs, rectum, bladder,
small and large bowels. These were used to analyze and compare the results of the two treatment
strategies that were under investigations.
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Chapter 6: Results
6.1 Study A: Prostate target motion relative to bony anatomy
The results of the analysis of study A are presented in the subsequent sections and have been used
to answer the research questions.
6.1.1 Interfractional prostate motion
Interfractional prostate motion occured in Right-Left (x), Anterior-Posterior (y) and Caudal-
Cranial (z) directions. Histogram and normal distribution approximation curves for these shifts;
∆x, ∆y and ∆z were made as shown in Figures 19 and 20 respwctively below;
Figure 19: Histogram for shifts in ∆x, ∆y and ∆z.
Figure 20: Normal distribution approximation curves in ∆x, ∆y and ∆z.
The above plots for ∆x, ∆y and ∆z showed that these shifts were approximated by normal distri-
butions and that much shift (i.e. prostate motion relative to bony anatomy) occured in AP and
CC directions.
A table of estimates for µpop and Σpop was as shown in Table 6.1.1 below:
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Table 6.1.1: Estimates of µpop and Σpop.
Patients, j µj(∆x), (RL) [mm] µj(∆y), (AP) [mm] µj(∆z), (CC) [mm]
1 -1.06 2.36 3.10
2 -0.35 4.97 -4.18
3 0.01 -0.57 0.27
4 1.17 1.16 1.25
5 0.23 -2.65 2.96
6 -0.50 -1.45 2.35
7 0.22 0.52 -0.43
8 -1.22 1.12 0.63
9 -0.36 -4.45 2.23
10 -0.46 -8.56 10.32
11 -0.26 0.22 -1.35
12 1.45 4.82 -0.89
13 -1.56 -0.96 0.92
14 0.61 -2.36 1.01
15 0.18 2.54 -3.41
16 -0.93 2.27 -0.73
17 0.75 -3.10 1.73
18 -0.37 0.79 -1.50
µpop -0.1 -0.1 0.8
Σpop 0.8 3.3 3.1
From table 6.1.1, µpop were estimated to be -0.1, -0.1 and 0.8 for ∆x, ∆y and ∆z respectivly. The
estimated Σpop were 0.8, 3.3 and 3.1 for ∆x, ∆y and ∆z respectivly.
Histogram and normal distribution approximation curves for systematic errors µj(∆x), µj(∆y)
and µj(∆z) were made as shown in Figures 21 and 22 below;
Figure 21: Histogram for µj(∆x), µj(∆y) and µj(∆z).
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Figure 22: Normal distribution approximation curves for µj∆x, µj∆y and µj∆z.
A table for SDj(∆x), SDj(∆y) and SDj(∆z), together with σpop for the population was as shown
in Table 6.1.2 below;
Table 6.1.2: Calculated SDj(∆x), SDj(∆x), SDj(∆z) and SDpop for the population.
Patients, j SDj(∆x) [mm], (RL) SDj(∆y), (AP) [mm] SDj(∆z), (CC) [mm]
1 1.39 4.45 1.19
2 0.81 3.34 3.32
3 2.21 1.29 0.93
4 0.84 2.02 1.03
5 1.54 2.90 2.39
6 0.95 2.09 2.37
7 0.91 1.59 1.02
8 0.81 1.38 2.21
9 0.86 1.92 1.61
10 0.98 3.72 4.85
11 0.73 2.72 1.95
12 0.85 2.62 2.44
13 0.87 3.04 2.42
14 1.10 1.64 2.17
15 0.67 0.96 1.88
16 0.88 2.55 0.82
17 1.28 1.98 1.03
18 0.71 1.56 2.51
σpop 1.1 2.5 2.2
Table 6.1.2 above shows that the estimated σpop were 1.1, 2.5 and 2.2 for LR, AP and CC respec-
tively.
Both the histogram and normal distribution approximation curves for random errors were also
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made as shown in Figures 23 and 24 below;
Figure 23: Histogram for SDj(∆x), SDj(∆y) and SDj(∆z).
Figure 24: Normal distribution approximation curves for SDj(∆x), SDj(∆y) and SDj(∆z).
6.1.2 Correlation in motion directions
Correlation coefficients between: ∆x and ∆y, ρ̂∆x∆y was 0.12; ∆x and ∆z, ρ̂∆x∆z was -0.13 and
∆y and ∆z, ρ̂∆y∆z was -0.73. This showed clearly that there existed a strong negative linear
correlation between y and z where as no linear correlation existed between x and y as well as x
and z. Scatter plots for the shifts in the different directions were also made as shown in Figures
25 - 27 below:
Figure 25: Scatter plot for x against y.
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Figure 26: Scatter plot for x against z.
Figure 27: Scatter plot for y against z.
6.1.3 PTV margins to account for prostate motion
Using the Van Herk’s margin recipe, the prostate margins when positioned on BA were calculated
as:
M = 2.5Σpop + 0.7σpop in mm. (20)
M∆x ≈ 2.8 mm (21)
M∆y ≈ 10.0 mm (22)
M∆z ≈ 9.4 mm, (23)
the CTV and its corresponding PTV would look like Figure 28 shown below:
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Figure 28: Illustration of PTV and CTV for the margins obtained in Equations 21 - 23.
6.1.4 Appropriate shifts for plan library construction
Three different prostate positions were chosen for this study. Due to correlation in the anterior-
posterior (AP) and cranial-caudal (CC) directions, the library consisted of 3 p/sv-CTVs: 2 p/sv-
CTVs shifted +/- 1.5 SD of the systematic error in AP (+/- 5.0mm) and CC (+/-4.6mm) direction
and 1 p/sv-CTV without shift (Figure 29).
Figure 29: Original prostate position (orange), shifted prostate position 1 (blue) in posterior/caudal
direction and shifted prostate position 2 (magenta) in anterior/cranial direction.
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6.2 Study B: Comparison of standard treatment with adaptive proton
therapy
6.2.1 Comparison of delivered dose to the CTVs
In this study, dose delivery simulation to CTV67.5, CTV60, CTV50, bladder, rectum, small bowel
and large bowel were looked at. The simulation of dose delivery to the different CTVs during each
session of the treatment for the patients considered for both the standard/conservative and plan
library treatments where as shown in Figures 30 - 35 below.
Figure 30: Delivered dose to CTV67.5 for patients in standard treatment strategy on each rCT.
From figure 30, three patients received doses lower than 95% (D98%) of the prescribed dose for at
least a treatment session; patient 4 for two treatment sessions while patient 2 and patient 5 for
one treatment session each. However, none of the patients received above 107% of the prescribed
dose.
Figure 31: Delivered dose to CTV67.5 for patients in plan library treatment strategy on each rCT.
Figure 31 revealed that two patients received doses lower than 95% (D98%) of the prescribed
dose for at least one treatment session with patient 2 for one treatment session and patient 4, two
tretament sessions while none received above 107% of the prescribed dose. From statistical analysis
(paired t-test) comparing the treatment strategies, it was seen that the mean doses to CTV67.5 for
the two strategies were approximately the same; approximately 66.06Gy and 66.08Gy for standard
and plan library strategies respectively for p(T ≤ t)=0.9.
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Figure 32: Delivered dose to CTV60 for patients in standard treatment strategy on each rCT.
Figure 32 showed that patient 4 had one tretament session with a dose less than 95% (D98%) of
the prescribed dose and patient 1 had four treatment sessions above 107% of the prescribed dose
and two treatment sessions with doses just bout 107% of the dose prescribed.
Figure 33: Delivered dose to CTV60 for patients in plan library treatment strategy on each rCT.
Figure 33 showed that patient 1 had one treatment session with higher dose than the maximum
prescribed dose of 107% and patient 4 had a lower dose below the 95% (D98%) of the prescribed
dose for one session. It was also seen, by statistical analysis (paired t-test), that the mean doses to
CTV60 were approximately the same; approximately 62.21Gy and 62.02Gy for standard and plan
library strategies respectively p(T ≤ t)=0.1.
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Figure 34: Delivered dose to CTV50 for patients in standard treatment strategy on each rCT.
Figure 34 showed that all patients had at least one treatment session with a dose less than 95%
(D98%) of the prescribed dose with two sessions for patient 1, four sessions for patient 2, three
sessions for patient 3, all the eight sessions for patient 4 and three sessions for patient 5. However,
none of the patients had a dose higher than 100% of the prescribed dose.
Figure 35: Delivered dose to CTV50 for patients in plan library treatment strategy on each rCT.
Figure 35 showed that all patients had at least one treatment session with a dose less than 95%
(D98%) of the prescribed dose with one session for patient 1, three sessions for patient 2, three
sessions for patient 3, all the eight sessions for patient 4 and three sessions for patient 5 while
none of the patients had a dose higher than 100% of the prescribed dose. Statistical analysis
(paired t-test) revealed that the mean doses to CTV50 were approximately 46.98Gy and 47,25Gy
for standard and plan library strategies respectively. The mean doses to CTV50 for both strategies
were approximately the same but a much better dose coverage was achieved with plan library.
6.2.2 Comparison of delivered doses to OARs
The results showed a reduction in the mean dose of approximately 3.1Gy gEUD for rectum (k=12)
with p(T ≤ t)=0.00004 and approximately 1.9Gy gEUD for bladder (k=8) with p(T ≤ t)=0.00009
using plan library strategy while the mean dose to the large and small bowels were approximately
the same for the two approaches. Mean gEUDs were approximately 29.7Gy and 29.8Gy with p(T
≤ t)=0.7 for large bowels (k=4) for standard and plan library approaches respectively while the
mean gEUDs for the small bowels (k=4) were approximately 24.44Gy and 24.41Gy with p(T ≤
t)=0.5 for standard and plan library strategies respectively.
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Chapter 7: Discussion and Conclusion
7.1 Discussion
In this master project we have estimated in a patient-population how prostate move in relation
to bony anatomy and used this to construct a plan library for use in proton therapy of high-risk
prostate cancer patients who simultaneously receive treatment to the prostate, seminal vesicles
and pelvic lymph nodes (study A). This plan library approach was also shown to be feasible in a
simulation study of five independent high-risk prostate cancer patients (Study B). Compared to
standard proton therapy, the plan library approach resulted in reduced estimated treatment doses
(gEUD) to the rectum and bladder while maintaining similar estimated treatment minimum doses
to the CTVs.
To our knowledge this is the first project investigating the use of a population-based plan
library in proton therapy of high-risk prostate cancer patients. Another study was conducted
where a patient-specific library of PTV was used in plan-of-the day adaptation for interfractional
motion mitigation [Wenjing C. et al., 2013]. Multiple images taken on different days were used
with delineations of both the target and OARs to create the plan library which was then used for
treatment. This method was tested for feasibility and effectiveness in a retrospective tretament-
planning which resulted into satisfactory target coverage with a slightly increased delivered dose
to the OARs [Wenjing C. et al., 2013]. Yet another study carried out on prostate cancer treatment
using proton therapy involved online adaptive procedure to mitigate the effect of prostate motion
relative to bony anatomy and was compared to non- adaptive procedure [Zhang M. et al., 2011].
It was established that the non-adaptive method resulted into a degradation in the delivered dose
while the adaptive procedure was effective depending on whether the technique used was two-field
opposing spot 3D-modulation or 24-field full arc distal edge tracking (DET) [Zhang M. et al.,
2011]. This study found out that the 3D-modulation was more robust than DET [Zhang M. et
al., 2011]. The reason was due to the number of beam angles with DET having more beam angles
and hence for any direction of prostate shift, there were always beams perpendicular to motion
direction leading to high doses [Zhang M. et al., 2011]. Compared to these methods, our method
is simpler as it requires only a single pCT for plan library generation and plan selection could be
performed without target delineation.
In our study, study A, from a population of 18 patients, it was established that there were
motion of prostate in all directions relative to bony anatomy. Greatest motion took place in the
AP and CC directions and least in the RL direction. This motion could have been due to a number
of sources, but no specific cause was identified in the study. A number of studies have been carried
out, compiled and reviewed regarding organ motion and its management [Langen K.M. et al.,
2001]. These studies ranges from position-related organ motion to interfractional organ motion.
It was seen from the different studies that there was no single specific value of motion but rather
a range of values, and all these were within the same range [Langen K.M. et al., 2001]. These
studies confirm our findings, that is; there is less motion in the RL direction compared to AP
and CC directions and that our values were in the range prescribed by other authors. Chris B. et
al. did a study to determine the target volume PTV margins for prostate [Chris B. et al., 2008].
Here the prostate position was localized using implanted gold seeds in the prostate with respect
to the bony anatomy and margins determined to find the degree of motion [Chris B. et al., 2008].
They found that the BA localization leads to a setup margin of 3.1mm, 8.9mm and 10.7mm in
the LR, IS and AP directions respectively, and that Σ were 0.9mm, 3.0mm and 3.5mm while σ
were 1.2mm, 2.0mm and 2.8mm in the LR, IS and AP directions respectively. These values were
similar to our findings. Furthermore, our study revealed that there existed a strong negative linear
correlation between two motion directions; AP and CC as was demonstrated in the scatter plot
(Figure 27). This literally meant there was simultaneous motion in the AP and CC direction
which could affect treatment. To mitigate this motion challenge, we constructed a plan library
with prostate in three different positions as well as one position where the prostate was not shifted
except larger margins were used. A challenge with the feasibility of a plan library approach is the
manual selection of treatment plans which limits the number of plans included in the plan library.
In this study we limited the number of plans to four (4). This was possible by exploiting the
correlation of motion in the anterior-superior direction and inferior-posterior direction established
in study A. Study B showed similar trends in the dose distributions uisng both the standard and
plan library strategies in terms of dose distributions to CTV67.5, CTV60 and CTV50. However,
the trend in dose distribution in CTV50 showed missing of the targets in most of the treatment
sessions by almost all the patients who were being used for the study for both strategies. This could
have been attributed to the delineation errors, errors due to skin motion with respect to internal
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anatomy, imaging errors due to arbitrary position of prostate or interference of the scanning process
and organ and setup errors. There was reduced doses to the rectum and the bladder using the
plan library approach while the gEUD to the small and large bowels showed no much difference.
The method of plan library proved to be a simple feasible method since you do not need target
delineation each time you should carry out a treatment in a given treatment session. However, it
is more cumbersome compared to the standard treatment approach.
7.2 Conclusion
Uncertainties such as setup errors and organ motions are inevitable during proton therapy just
like in any other radiotherapy technique although this treatment option has proven to be effective.
This therefore means measures have to be put in place to ensure treatment is carried out in the
best way possible. One of the ways we tried to investigate in this master project was to determine
the degree of interfractional prostate motion relative to the bony anatomy and shift the prostate
accordingly. This investigation was based on a population of patients to help determine margins
that were used to create the PTVs and to construct a plan library. This plan library construction
aimed at establishing the doses delivered to the targets compared to the standard approach as well
as comparing the gEUD to the rectum and bladder with respect to the standard approach.
This approach indeed resulted in reduced estimated treatment doses (gEUD) to the rectum
and bladder while there was a comparable estimated treatment minimum doses to the CTVs as
well as the small and large bowels. The plan library approach based on a population information
about prostate motion relative to bony anatomy thus proved to be feasible.
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a) When you login to the Eclipse TPS; you go to quicklinks, choose imaging and then image reg-
istration and finally click ok.
b) In the top dialogue box, you then search for the patient you want to do registration on, in
this case zzprostHUH23.
48
c) You then go to the rCT you want to do registration and double click to open.
d) Click registration and choose automatic matching.
49
e) Rename the registration e.g BONNY and then select the source image which is the pCT as
well as the rCT which is the target.
f) After clicking OK, a box (registration box) appears that can be adjusted to cover all the areas of
interest. A volume of interest was placed around the pelvic bones including the prostate to restrict
the registration area. Also a dialogue box pops up that you can turn off rotation as well as choose
intensity range.
g) In this study, intensity of bones was being used as the registration was based on BA, so the box
for bones was checked.
50
h) After the box was adjusted to cover all the bones in the area of interest, start the registra-
tion by clicking on start.
i) When the registration is finished then you click close.
51
j) If it is satisfactory, the registration is done otherwise adjust the box to cover the bones again as
you scroll from top to bottom and start the auto match again.
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APPENDIX B
Procedure for creating structures in conservative treatment planning
a) When you login to the Eclipse TPS; you go to contouring, choose the patient you want to create
the different structures, choose ”insert” then new structure and finally click ok or right click on any
existing structure and choose create structure. This will give you an option to name the structure,
choose the type of structure and change the colour of the structure.
b) Highlight the structure newly created empty structure and click create margin. This will give
you an option to choose the structure from which the structure will have its margin around or
within as well as choose the margin for the different directions and you click okay. The structure
will have been created.
c) To create PTV50, use CTV50 plus 5 mm isotropical margin, then create PTV50Left and
PTV50Right by deleting the part which should not be included. Use Boolean to include PTV6,
using PTV50left Or PTV60.
d) To create PTV60, use CTV60 plus 5 mm margin in the Left-Right direction and 10 mm other-
wise.
53
e) To create PTV67.5, use CTV67.5 plus 3mm margin in the Left-Right direction and 10mm
otherwise.
f) Create help volume, helpPTV50 from PTV50, crop towards PTV60 with 5 mm margin.
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g) Create normal tissue (pink), 4 cm margin (1 cm cranial/caudal) around PTV50. Post processing:
Extraction, keep 1 largest and connect 4 cm. Crop normal tissue towards PTV50 with 5 mm
margin, crop towards PTV60 with 5mm margin and crop towards body with 1-1.5 cm margin.
NB: Do connection before cropping.
h) Create under67.5 around PTV67.5 with a margin of 2cm. Crop 5 mm towards PTV67.5.
i) Create out volumes for BladderOut (pink), and crop 5mm towards PTV60 and PTV50.
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j) Create IntestineOut and crop 5 mm towards PTV50.
k) Create RectumOut (bold pink) and Crop 5 mm towards PTV60.
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APPENDIX C
Procedure for creating structures in plan library treatment planning
a) When you login to the Eclipse TPS; you go to contouring, choose the patient you want to create
the different structures, choose ”insert” then new structure and finally click ok or right click on any
existing structure and choose create structure. This will give you an option to name the structure,
choose the type of structure and change the colour of the structure.
b) Highlight the structure newly created empty structure and click create margin. This will give
you an option to choose the structure from which the structure will have its margin around or
within as well as choose the margin for the different directions and you click okay. The structure
will have been created.
c) Create PTV50; use CTV50 plus 5 mm isotropical margin.
d) Create PTV50Left and PTV50Right by deleting the part which should not be included. Use
Boolean to include PTV60, using PTV50left Or PTV60 for left and ”PTV50Right or PTV60” for
right.
e) Use Boolean to include PTV60, using PTV50left or PTV60 for the PTV50left and PTV50Right
or PTV60 for
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f) Create PTV60; use CTV60 plus a 5 mm isotropic margin.
g) Create PTV67.5; use CTV67.5 plus a 5mm isotropic margin.
h) Create help volumes for helpPTV50 from PTV50, crop towards PTV60 with 5 mm margin.
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i) Create normal tissue, 4 cm margin (1 cm cranial-caudal) around PTV50. Post processing:
Extraction, keep 1 largest, connect 4 cm. Crop normal tissue towards PTV50 with 5 mm margin,
crop towards PTV60 with 5mm margin and crop towards Body with 1-1.5 cm margin. NB:
connection before crop.
j) Create under67.5 around PTV67.5 with a margin of 2cm. Crop 5 mm towards PTV67.5.
k) Create out volumes for BladderOut and crop 5mm towards PTV60 and PTV50.
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l) Create out volumes of RectumOut, Crop 5 mm towards PTV60.
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APPENDIX D
Procedure for plan selection
a) Create a new course and copy all the plans to that new course.
b) Create a verification plan for each of the positions of the prostate and remember to use ”current
structure”.
c) Use the registration data and choose the most appropriate plan that seems to be the right
directional shift (compared to AP=5, CC=4.6) for each rCT.
d) Drag and drop the chosen plan.
e) Press CTRL and right click on the rCT you want to choose the plan library for.
f) Inspect how the CTV60 and CTV67.5 for the rCT fit with the PTV60 and PTV67.5 of the
pCT.
g) Copy the verification plan for the chosen plan that fitted well to its corresponding rCT and
re-calculate the dose.
To create a verification plan; select the plan and go to;
1. Planning:
2. Create verification plan:
3. Select the location of the plan, in this case C4PL:
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4. Select ”use current” followed by next:
5. When done with creating the verification plan, copy and paste in each registration of the rCT
and calculate the monitor units.
To create verification plans based on GM and bony anatomy registrations:
1. Define user origin inside prostate. This is done by dragging the mark into the prostate.
2. Create user origin structure in user origin. This is done by going to create new structure and
use the brush to fit it onto the mark.
3. Define user origin in the same position on the GM registration rCT. This is done by pressing
CTRL and right clicking the appropriate rCT; then drag the lines to cross in the mid-point.
4. Create GM verification plan (Under planning). Remember to select structure for each GM
registration.
5. Do dose recalculation.
6. Name ID- in our case Bonny RPXGM.
7. Then go to registration and delete the registration based on GM.
8. Note the isocentre of the robust plan.
9. Copy Bonny RP to BonnyX registration image.
10. Create verification plan, change isocentre, change coordinates and scale the dose.
11. Create verification plan.
12. Rescale dose to 67.5 by changing fractions to 25.
13. Create Bonny RPXbony plan.
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